Ovarian Cancer | Disease Landscape & Forecast | G7 | 2024
The treatment of ovarian cancer has been transformed by the angiogenesis inhibitor bevacizumab and the PARP inhibitors olaparib (Lynparza; AstraZeneca / Merck & Co.), niraparib (Zejula; GSK), and rucaparib (Rubraca; Pharma&), particularly for patients with HRD and deleterious BRCA mutations. A highly promising biomarker, the folate receptor-alpha (FRα) protein is now a target in the treatment of advanced disease. In November 2022, mirvetuximab soravtansine (Elahere; ImmunoGen / AbbVie) entered the U.S. market as the first ADC targeting patients with high FRα-expressing tumors (TPS ≥ 75%; PS2+). A second FRα-targeted ADC, luveltamab tazevibulin (Luvelta; Sutro Biopharma), is expected to induce antitumor responses in a broader FRα-expressing population (TPS > 25%), thus increasing the number of patients eligible for treatment.
Questions answered
- What is the size of the clinically and commercially relevant drug-treatable ovarian cancer population, and how will drug-treatment rates change over time?
- What is the current treatment landscape for ovarian cancer? What are interviewed experts’ insights on current therapies?
- What are the most promising agents in the late-phase pipeline, and how will they shape the future of the ovarian cancer market?
- What are the main drivers of and constraints in the treatment of ovarian cancer, and how will this market evolve over the forecast period?
Geography: United States, EU5, Japan
Primary research: ~18 country-specific interviews with thought-leading medical oncologists. Supported by survey data collected for this and other Clarivate research.
Epidemiology: Diagnosed incidence by country and disease stage; clinically and market-relevant drug-treatable populations.
Forecast: 10-year, annualized, drug-level sales and patient share of key ovarian cancer therapies through 2033, segmented by brands / generics / biosimilars and epidemiological subpopulations.
Drug treatments: Coverage of key current and emerging therapies.
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Key features
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
